A detailed history of Brevan Howard Capital Management LP transactions in Neurocrine Biosciences Inc stock. As of the latest transaction made, Brevan Howard Capital Management LP holds 6,093 shares of NBIX stock, worth $761,625. This represents 0.0% of its overall portfolio holdings.

Number of Shares
6,093
Previous 3,984 52.94%
Holding current value
$761,625
Previous $548,000 27.92%
% of portfolio
0.0%
Previous 0.0%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$114.58 - $153.15 $241,649 - $322,993
2,109 Added 52.94%
6,093 $701,000
Q2 2024

Aug 14, 2024

SELL
$130.86 - $143.19 $280,825 - $307,285
-2,146 Reduced 35.01%
3,984 $548,000
Q1 2024

May 15, 2024

BUY
$130.4 - $143.74 $81,369 - $89,693
624 Added 11.33%
6,130 $845,000
Q4 2023

Feb 14, 2024

BUY
$106.07 - $132.76 $584,021 - $730,976
5,506 New
5,506 $725,000

Others Institutions Holding NBIX

About NEUROCRINE BIOSCIENCES INC


  • Ticker NBIX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 95,639,296
  • Market Cap $12B
  • Description
  • Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...
More about NBIX
Track This Portfolio

Track Brevan Howard Capital Management LP Portfolio

Follow Brevan Howard Capital Management LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Brevan Howard Capital Management LP, based on Form 13F filings with the SEC.

News

Stay updated on Brevan Howard Capital Management LP with notifications on news.